Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy
Hyperemesis Gravidarum, Nausea Gravidarum, Vomiting of Pregnancy
About this trial
This is an interventional treatment trial for Hyperemesis Gravidarum focused on measuring capsaicin, nausea, vomiting, pregnancy, hyperemesis gravidarum
Eligibility Criteria
Inclusion Criteria:
- Pregnant women in the first trimester (0-14 weeks gestation)
- Presenting to the emergency room at Women & Infants Hospital in Rhode Island with a chief complaint of nausea and vomiting
- English or Spanish speaking
- Have not taken an anti-emetic such as Reglan or Zofran within the 6 hours prior to presentation
Exclusion Criteria:
- Allergy to Reglan, capsaicin or Zofran
- Another identifiable source for nausea and vomiting (i.e. gastritis, COVID, diabetic ketoacidosis)
- Molar pregnancies,
- Patients with a history of gastroparesis
- Patients with a history of preexisting diabetes mellitus
Sites / Locations
- Women and Infants HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Intervention group
Placebo group
Participants will receive IV fluid bolus of 1000cc of lactated ringers, metoclopromide 10mg IV and will have 5g of 0.075% capsaicin cream applied to their abdomen. Participants will indicate the severity of their symptoms immediately prior to administration of metoclopromide, at time 0 and every 30 minutes for a total of 120 minutes after administration of the first medications (or discharge) using a 10 cm visual analogue scale (VAS)11,12. The scale will be provided in English or Spanish as appropriate. If at the 90-minute time mark the patient does not report improvement of their symptoms, odansetron 8mg IV will be administered.
Participants will receive IV fluid bolus of 1000cc of lactated ringers, metoclopromide 10mg IV and will have 5g of placebo cream applied to their abdomen. Participants will indicate the severity of their symptoms immediately prior to administration of metoclopromide, at time 0 and every 30 minutes for a total of 120 minutes after administration of the first medications (or discharge) using a 10 cm visual analogue scale (VAS). The scale will be provided in English or Spanish as appropriate. If at the 90-minute time mark the patient does not report improvement of their symptoms, odansetron 8mg IV will be administered.